Nobel Biocare receives EU Medical Device Regulation Quality Management Certificate

Nobel Biocare is pleased to announce the receipt of the EU Medical Device Regulation (MDR) Quality Management System certification by its Notified Body, the BSI Group, the Netherlands B.V. This signifies that Nobel Biocare’s Quality Management System, and the corresponding first group of products, meet the requirements of the new MDR implemented by the European Union.

“BSI is delighted to have successfully issued our first Dental devices, Class I Reusable and Class IIb Well Established Technology certificates under the new EU Medical Device Regulation (MDR), on behalf of Nobel Biocare, another important step within BSI’s rapidly increasing  MDR certification activity.”  Gary Slack. Senior Vice President – Global Medical Devices, BSI

Achieving this important milestone establishes Nobel Biocare as one of the first companies to achieve MDR certification in the dental device field.

“Receiving the MDR certificate is an important milestone for Nobel Biocare and shows that we are right on track in our efforts to achieve MDR certification * for our full portfolio,” commented Nobel Biocare Systems president, Patrik Eriksson. “It demonstrates the commitment to our customers and their patients to ensure that our products and solutions remain available as new regulations go into effect. This continues our long-standing commitment of meeting the highest quality and scientific standards for the safety and well-being of patients treated with our products and solutions.”

Implemented by the European Union in 2017, the new Medical Device Regulation was due to become fully active on May 26, 2020, now confirmed to be delayed by a year, with a transition period lasting until May 2024. It will replace the current Medical Device Directive and the EU's Directive on active implantable medical devices.

Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company's portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including Nobel Biocare N1™, NobelActive®, NobelParallel™, and the All-on-4® treatment concept), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), prefabricated prosthetics, and a wide variety of regenerative solutions (creos™). Products are supported by a single digital platform for imaging, diagnostics, and treatment planning (DTX Studio™ suite), and guided and navigated surgery (NobelGuide® and X-Guide®). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, and production takes place at sites located in the United States and Sweden. Products and services are available in over 50 countries through subsidiaries and distributors. Nobel Biocare is part the Envista family, one of the largest global dental products companies with more than 30 trusted dental brands. For more information, please visit

Related articles